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Abstract
Patients with antiphospholipid syndrome are at increased risk for recurrent arterial and venous
thrombosis and therefore benefit from long term warfarin therapy. The optimal duration of
warfarin therapy after a first venous thromboembolic event is however a matter of some
controversy and many questions remain unanswered. After reviewing and analysing the available
evidence, we discuss some common scenarios in everyday clinical practice where treatment
decisions are difficult.
Introduction
Patients with antiphospholipid syndrome, an acquired
autoimmune thrombophilia, are at risk of both arterial
and venous thromboembolic events [1,2]. Indeed, the
antiphospholipid syndrome (APS) is defined by vascular
thrombosis and/or pregnancy morbidity occurring in the
setting of persistently positive antiphospholipid antibod-
ies (aPL) [3]. At least one clinical and one laboratory cri-
teria are required to classify a patient with APS [3].
Relevant aPL laboratory criteria include lupus anticoagu-
lant (LA) and moderate to high titres of anticardiolipin
antibodies (aCL), which have tested positive on two occa-
sions at least 12 weeks apart [4]. Recently anti-β2 glyco-
protein I antibodies were included in the laboratory
classification criteria, although the assays lack standardi-
zation and this inclusion has been somewhat controver-
sial [4]. Virtually any vascular territory (venous or arterial)
can be affected but deep vein thrombosis of the lower
limbs with or without pulmonary emboli is the most
common clinical presentation of thrombosis [2].
Antiphospholipid syndrome and antiphospholipid anti-
bodies can occur either alone or in association with sys-
temic connective tissue diseases, most commonly
systemic lupus erythematosus (SLE). Approximately half
the patients with APS have no underlying systemic
autoimmune disease. In SLE, the prevalence of aPL ranges
from 12 to 30% for aCL and 15 to 31% for LA, but the
prevalence of APS is 10% and this is known to increase
with follow – up with an estimated cumulative prevalence
of around 30% [1,2,5].
The overall risk of thrombosis is increased in patients with
aPL [1]. These antibodies can be identified in 4 to 21% of
patients presenting with venous thromboembolism, a sig-
nificantly higher prevalence than that observed in healthy
individuals (1 to 5%) [6-8]. In young patients with stroke,
18% were found to have aPL [9]. LA seems to be more pre-
dictive of thrombosis than aCL (odds ratio 11 for LA and
1.6 for aCL, CI 95%) [10]. However, the risk associated
with aCL rises when only moderate to high titres are con-
sidered [11]. Moreover, in patients with SLE and aPL, the
odds ratio for venous thromboembolism was 6.32 when
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compared with patients without these antibodies [12]. On
the other hand, the risk of thrombosis is likely to be low
among healthy patients with incidental and transiently
positive aPL (< 1% per year) [7]. In patients with aPL,
recurrent thromboembolic events are common. A high
risk of recurrence has been suggested in retrospective stud-
ies, with recurrence rates as high as 69% over 6 years of
follow up [13-15].
Thus, patients with APS are considered at high risk of
thromboembolic events and warrant effective evidence –
based antithrombotic strategies. In patients with both
arterial and venous thromboembolic events or more than
one thrombotic event there is a consensus that indefinite,
life long, anticoagulation therapy is essential to reduce the
risk of recurrent thrombotic events [7,16]. However,
recurrent arterial events most frequently follow initial
arterial events and similarly initial venous events tend to
recur as venous events [15]. Following an arterial or
venous thrombotic event, secondary prevention with
indefinite anticoagulation, initially with low molecular
weight heparin or unfractioned heparin, acutely, followed
by warfarin is the standard of care. However, defining the
adequate length of warfarin therapy remains very contro-
versial [7,16-21]. Given these controversies, recurrent
thrombosis in the context of APS and the optimal dura-
tion of warfarin treatment for secondary prevention of
thrombosis will be discussed. The management of preg-
nancy loss in APS is beyond the scope of this review.
From the evidence to the recommendations
Rosove et al and Khamashta et al retrospectively evaluated
70 and 147 patients with APS for a mean of 5 and 6 years
from the first thromboembolic event and reported recur-
rent thromboembolic events (arterial and/or venous) in
53 and 69% of the patients, respectively [13,15]. Finazzi
et al and Turiel et al prospectively followed up one cohort
of 360 unselected patients with aPL and one cohort of 56
patients with primary APS over 4 and 5 years, respectively
[22,23]. Previous thrombosis (arterial or venous) and per-
sistent high titres of anticardiolipin antibodies (IgG > 40
GPL U) were identified as independent predictors of
thrombotic events. (Table 1)
Recurrent venous thrombosis (Table 2)
• Risk of recurrence after stopping anticoagulation therapy
In a retrospective study by Derksen et al, 12 of 19 patients
with APS and venous thrombosis had recurrent throm-
boembolic events (63%), all of which occurred in patients
in whom anticoagulation had been stopped (median fol-
low up: 8 years) [14].
Recurrent events occurred more frequently in the first 6
months after stopping anticoagulation therapy [15]. Kha-
mashta et al calculated the recurrence rate in this period to
be 1.30 events per year [15]. This recurrence rate is higher
than in patients with a first idiopathic deep vein thrombo-
sis after 3 months of treatment (0.27 events per year) [24].
Schulman et al conducted a prospective study in which
412 patients without evidence of malignancy or heredi-
tary thrombophilia were anticoagulated for six months
after a first venous thromboembolic event and followed
up for 4 years [25]. IgG aCL measured once 6 months after
the thrombotic events were positive in 15% of the
patients. The risk of recurrence after four years was 29% in
patients with aCL and 14% in patients without these anti-
bodies (risk ratio 2.1; 95% CI 1.3–3.3; p = 0.0013). The
calculated rate of recurrence was 0.10 per year in patients
with aCL and 0.04 per year in patients without aCL. A sim-
ilar risk of recurrence was reported at 10 years of follow up
in unselected patients randomly allocated to either 6
weeks or 6 months of warfarin after a first venous throm-
boembolic event [26].
Kearon et al reported that aPL positive patients having
completed 3 months warfarin for idiopathic venous
thromboembolism had a hazard ratio for recurrence of 4
(95% CI, 1.2 – 13) when compared to patients without
these antibodies (p = 0.03) [24].
• Risk of recurrence on anticoagulation therapy
Long term anticoagulation in patients with venous throm-
boembolism reduces the risk of recurrence and this was
confirmed in a meta – analysis [27,28]. Kearon et al quan-
tified a 95% risk reduction when warfarin therapy was
extended over 3 months [24]. One meta – analysis, how-
ever, has shown that the risk of recurrent venous throm-
boembolic events decreased over time reaching
stabilization at 9 months after the first event independ-
ently of the duration of anticoagulation [29]. In fact, the
incremental benefit of prolonging anticoagulation was
shown to decrease as the duration of anticoagulation
increases [28]. Beyond 6 months the magnitude of risk
reduction tends to become slimmer and therefore the
benefit of maintaining treatment may depend on the esti-
mated individual risk of recurrence [28].
In APS however, the available studies suggest that long
term oral anticoagulation therapy is beneficial after a
thromboembolic event. Derksen at al reported a 100%
probability of being free of recurrence at 8 years in
patients with APS and a venous thromboembolic event on
anticoagulation therapy compared to 22% in those in
whom anticoagulation had been stopped (p < 0.00001)
[14]. Khamashta el al, also in a retrospective study,
reported that patients with APS kept on oral anticoagulant
treatment (target INR = 3) had a 90% probability of being
free of recurrences (arterial or venous) over 5 years [15].
Schulman et al prospectively followed up 211 patientsJournal of Autoimmune Diseases 2008, 5:6 http://www.jautoimdis.com/content/5/1/6
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tested for aCL randomly allocated to either 6 months war-
farin or indefinite anticoagulation after a first recurrent
venous thromboembolic event [25]. In the 6 month treat-
ment group 20 out of 90 (22%) patients without aCL and
3 out of 15 (20%) with aCL had recurrences. In the indef-
inite treatment group, 2 out of 87 (2%) patients without
aCL and 1 out of 19 (5%) with aCL had recurrences,
although all three recurrences occurred in patients who
had stopped anticoagulation [25].
Taken together, these studies suggest that indefinite long
term anticoagulation is warranted in patients with venous
thrombosis and persistently positive aPL. However, one
should be cautious about interpreting the risk of recurrent
thrombosis and specifically the risk of recurrent venous
events. Firstly, the available data comes from the few stud-
ies conducted (3 retrospective studies and 4 prospective
studies). Most only included small numbers of patients,
many with an underlying systemic autoimmune disease,
and had no control groups. In one study, patients were
tested only once for aCL and many had low titre antibod-
ies and therefore did not fulfil the criteria for APS. Arterial
and venous events were frequently considered together in
the evaluation of recurrence and these studies had very
different uncontrolled treatment strategies. This can be
confusing and hampers the interpretation and generaliza-
tion of the results. Moreover in none of these studies were
other risks factors for thrombosis in patients with aPL
extensively evaluated.
All in all, the existing data is not comprehensive enough
to strongly support decisions on the optimal duration of
Table 1: Recurrent thrombosis in the patients with antiphospholipid antibodies
Study design N Mean age
Years
Entry 
criteria
Patient 
Characteristics
Mean 
Follow up
Years
Patients with 
recurrent 
events
No. (%)
Number of 
recurrent 
events
All 
(arterial/venous)
Reference
Retrospective 70
48W
22M
45.5 ± 17.3 aPL (aCL/LA) + 
arterial/venous 
thrombosis (1st 
event)
PAPS 51
SLE 14
ITP 5
5.2 37/70 (53%) 54 Rosove MH et 
al. Ann Intern 
Med 1992
Retrospective 19
16W
3M
26
(15–40)
aPL (aCL/LA) + 
venous 
thrombosis (1st 
event)
PAPS 1
SLE 12
Lupus like 6
8 12/19 (63%) 37 (3/34) Derksen R et al. 
Ann Rheum Dis 
1993
Retrospective 147
124W
23M
32
(14–66)
aPL (aCL/LA) + 
arterial/venous 
thrombosis (1st 
event)
PAPS 62
SLE 66
Lupus like 19
7 101/147 (69%) 186 (75/111) Khamashta M 
et al. N Eng J 
Med 1995
Prospective 360
242W
118M
39
(2–78)
aPL (aCL/LA) 
(117 aPL pt with 
previous arterial/
venous 
thrombosis)
SLE 69
Lupus like 66
4 25/117 (21.3%) 25 Finazzi G et al. 
Am J Med 1996
Prospective 412
181W
231M
60.2 Venous 
thrombosis (1st 
event) allocated 
6 months 
warfarin
- 4 20/68 aCL+ 
(29%)
47/344 aCL- 
(14%)
67 (-/67) Schulman S et 
al. Am J Med 
1998
Prospective 56
48W
8M
37 ± 10 APS (aPL + 
thrombosis and/
or fetal loss)
(43 patients with 
previous arterial/
venous 
thrombosis)
PAPS only 5 14/43 (32.5) 16 (10/6) Turiel M et al. 
Stroke 2005
W – women; M – men; aPL – antiphospholipid antibodies; aCL – anticardiolipin antibodies; LA – lupus anticoagulant; PAPS – primary 
antiphospholipid syndrome; SLE – systemic lupus erytematosus; Lupus like – Lupus like disease; ITP – chronic idiopathic thrombocytopenic purpura.Journal of Autoimmune Diseases 2008, 5:6 http://www.jautoimdis.com/content/5/1/6
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therapy after a first venous thromboembolic event or even
whether anticoagulation therapy can be safely discontin-
ued in patients with APS. It is not possible to predict
which patients will have recurrent thromboembolic
events. Ideally, therapy should be continued as long as
there is proven benefit for the patient without incurring a
significantly increased risk of bleeding. Both in patients
with and without APS on warfarin the risk of major bleed-
ing is 2 to 3% per year [7]. Thus optimal duration of treat-
ment is somewhere between the risk of thrombosis and
the risk of bleeding.
On the other hand, as far as intensity of treatment is con-
cerned, Crowther MA et al, in a randomized double blind
trial including 117 patients with previous thrombosis
(mainly venous) fulfilling criteria for APS, demonstrated
that high intensity warfarin therapy (target INR 3.1 – 4.0)
was not superior to moderate intensity warfarin therapy
(target INR 2.0 – 3.0) [30]. Their results suggested there-
fore that in patients with APS, moderate intensity warfarin
therapy is adequate for secondary prevention of recurrent
venous thromboembolism.
Based on the available data, the American College of
Chest Physicians recommends for patients with APS
and a venous thromboembolic event, warfarin therapy
with a target INR of 2.5 (Grade 1A) for 12 months
(Grade 1C+), and suggests that indefinite anticoagulant
therapy should be considered (Grade 1C) especially for
recurrent events [16].
Recurrent arterial thrombosis
Based on the retrospective and prospective studies men-
tioned above (which mostly involved arterial and venous
events together) long term, life long, high intensity warfa-
rin therapy is empirically recommended as secondary pre-
Table 2: Recurrent thrombosis in patients with antiphospholipid antibodies and duration of anticoagulation treatment
Study design N Mean follow up Results Reference
Retrospective 70 pt with aPL + arterial/
venous thrombosis (1st event)
5.2 years Recurrence rates (per patient year):
▪ 0.19 for no treatment, 0.32 for aspirin, 0.57 
for warfarin INR = 1.9, 0.07 for warfarin 2.0 = 
INR = 2.9 (p = 0.12)
▪ 0.00 for warfarin INR = 3.0 (p < 0.001)
Rosove MH et al. Ann 
Intern Med 1992
Retrospective 19 pt with aPL + venous 
thrombosis (1st event)
8 years Probability of survival free from venous 
thrombosis (Kaplan Meyer method):
▪ 100% in patients kept on warfarin vs. 22% in 
patients in whom warfarin was stopped – log 
rank test p = 0.000007
Derksen R et al. Ann 
Rheum Dis 1993
Retrospective 147 pt with aPL + arterial/
venous thrombosis (1st event)
7 years Recurrence rates (events per year):
▪ 0.29 for no treatment
▪ 0.015 for INR > 3, 0 for INR > 3 + aspirin 
(p < 0.001)
Probability of survival free from thrombosis 
(Kaplan Meyer method):
▪ 90% in patients kept on warfarin INR > 3 + 
aspirin vs. 30% in patients on no treatment 
(5 years)
Khamashta M et al. N Eng J 
Med 1995
Prospective 211 pt with a 1st recurrent 
venous thrombosis
4 years Recurrence rates:
▪ 3/15 pt aCL+ (20%) and 20/90 pt aCL- (22%) 
allocated 6 months warfarin
▪ 1/19 pt aCL+ (5%) and 2/87 pt aCL- (2%) 
allocated indefinite warfarin therapy
Schulman S et al. Am J Med 
1998
Prospective 162 pt with venous 
thrombosis (1st idiopathic 
event) having completed 3 
months of warfarin, allocated 
to either placebo or further 24 
months warfarin
10 months Total of 8 aPL +/150 pt tested 
(aPL prevalence 5%)
Recurrence rates:
▪ 4/6 aPL pt that completed only 3 months 
warfarin (placebo group) – HR (95%CI) of 4 
when compared to patients without aPL.
All patients 162; placebo group 83; warfarin 
group 79
Kearon C et al. N Eng J 
Med 1999
aPL – antiphospholipid antibodies; aCL – anticardiolipin antibodies; CI – confidence interval; HR – hazard ratio; INR – international normalized 
ratio; pt – patientsJournal of Autoimmune Diseases 2008, 5:6 http://www.jautoimdis.com/content/5/1/6
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vention for persistently positive aPL patients following an
arterial thrombotic event (Table 2) [13,15,22,23]. Clini-
cally, ischemic stroke is by far the most frequent arterial
thromboembolic manifestation in APS and the risk of
recurrent ischemic stroke is considered to be high [7].
• Ischemic Stroke
In unselected patients, ischemic stroke tends to occur at
older age and in the presence of other risk factors, such as
atrial fibrillation, hypertension, high cholesterol, athero-
sclerosis, diabetes mellitus and smoking [31]. Patient
management is directed at secondary prevention of recur-
rent events with antithrombotic therapy and control of
the vascular risk factors. The current standard of care for
patients with ischemic stroke and atrial fibrillation is long
term adjusted dose warfarin to target INR 2.0 – 3.0
[16,31]. In patients with thrombotic non-embolic
ischemic stroke, however, warfarin therapy with a target
INR of 1.4 – 2.8 was not found to be superior to aspirin in
the prevention of recurrent ischemic stroke, and, in these
patients, current recommendations favour antiplatelet
therapy [16,32].
In APS, stroke tends to occur at younger ages. In several
case series, stroke in patients with aPL was shown to occur
at an average age two decades younger than in the general
population [33,34]. Indeed, in a recent systematic review,
aPL were confirmed to be an independent risk factor for
incidental ischemic stroke, although data on their role in
recurrent ischemic stroke was found to be weaker and
conflicting [34]. Nonetheless, once ischemic stroke
occurs, secondary prevention becomes a major issue.
Stroke management in APS patients is a matter of signifi-
cant debate and controversy. Older restrospective studies
have shown recurrent thrombotic events events to be sig-
nificantly reduced under warfarin therapy with a target
INR > 3.0 with or without low dose aspirin [13,15].
Recently, Ruiz-Irastroza et al, in a retrospective case series
of 66 patients with definite APS and previous thrombosis
(arterial in 77% of patients), reported a high recurrent rate
of thrombosis, 9.1 cases per 100 patients-years (95% CI,
3.3 – 19.6), most ocurring at INR between 2.1 and 2.6
[35].
However, in 2003, Dersken et al prospectively followed
up 8 patients with ischemic stroke as a first manifestation
of APS treated with low dose aspirin for 8.9 years [36].
Recurrent stroke rate was 3.5 per 100 parients years (95%
CI, 0.4 – 12.5), a recurrence rate similar to that expected
in aPL negative patients with ischemic stroke.
In 2004, the APASS study (Antiphospholipid Antibodies
and Stroke Study) proved to be very controversial in the
management of stroke in APS. In this study, a large pro-
spective study within the WARSS study (Warfarin vs Aspi-
rin Recurrent Stroke Study), 1770 aPL positive patients
with ischemic non cardioembolic stroke were randomly
allocated either to aspirin (325 mg/d) or adjusted dose
warfarin (target INR 1.4–2.8) [37]. The presence of aPL
among patients with ischemic stroke did not predict sub-
sequent tromboembolic events over a two year follow up
(24% recurrent thrombotic events in both aPL and non
aPL patents; adjusted RR 0.98; 95%CI 0.80–1.20; p =
0.83). Moreover, the risk of recurrent thromboembolic
events in aPL positive patients with ischemic stroke was
not modified by the type of treatment (aspirin 325 mg
versus warfarin with a median INR of 2) [37]. Interest-
ingly, the small group of 120 patients who tested positive
for both aCL and LA had a higher risk of thromboembolic
events or death regardless of the type of treatment (RR
1.41; 95%CI 0.99–2.02; adjusted p = 0.06; LA × aCL inter-
action adjusted p = 0.02) [37]. The authors' main conclu-
sions were: a) LA or aCL testing was not important for
prognosis or treatment of unselected patients with recent
ischemic stroke; b) in patients with stroke who tested pos-
itive for aPL, warfarin therapy with targer INR 1.4 – 2.8
was not associated with fewer recurrent events than aspi-
rin.
Several important flaws in this study hamper the general-
ization of the results to the APS population [37,38]. The
average age of the study group was above 60, which is
higher than most APS patients groups. Testing for aPL was
done only once and the aPL titres were usually low. As
such, the classification criteria for APS were not met.
Moreover, the empirically recommended high intensity
warfarin treatment (target INR > 3) or even the moderate
intensity warfarin treatment (target INR 2–3) was not
tested. Their inclusion as treatment arms might have led
to different results. As a result of these flaws, this study has
been widely discredited by opinion leaders as being unre-
liable evidence on which to base recommendations for
stroke therapy in APS patients.
• Non cerebral arterial thrombotic events
Virtually any other arterial vascular territory may be
affected in APS. Examples include coronary artery disease,
namely acute myocardial infarction, intestinal ischemia
and glomerular thrombosis, among others. The optimal
treatment of these patients is uncertain and management
is based on expert opinion. Currently, long term indefi-
nite warfarin therapy (target INR 2.0 – 3.0) is empirically
recommended [7].
Overall, these results are not strong enough to modify
the current expert based treatment recommendations
for secondary prevention of arterial thromboembolism
in APS.Journal of Autoimmune Diseases 2008, 5:6 http://www.jautoimdis.com/content/5/1/6
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Data from the APASS however suggests that older
patients with a first ischemic stroke and a single posi-
tive aPL on repeated testing and no other risk factors
such as atrial fibrillation or systemic autoimmune dis-
eases can be managed in the same way as the general
population with ischemic stroke.
Alternative therapies to Warfarin
Warfarin's anticoagulant effect is due to the inhibition of
vitamin K and inherent reduction of vitamin K dependent
clotting factors. It is the most widely used drug for long
term anticoagulation therapy. However it is a cumber-
some drug to use. Warfarin has a narrow therapeutic
range, many other drugs and diet can interfere with its
anticoagulant effect in either direction, and its use is asso-
ciated with a 3% risk of major bleeding per year [7,39].
Therefore, frequent blood monitoring is needed for dose
adjustment and control. Bleeding is known to occur even
within the therapeutic range and several factors including
hypertension, use of aspirin or nonsteroidal anti-inflam-
matory drugs, gastrointestinal inflammation or ulcera-
tion, older age, patient reliability, warfarin interactions,
clotting factor mutations (Factors IX and XI) and von Wil-
lebrand mutations, can contribute to the risk of bleeding
[38]. Moreover, warfarin is teratogenic in the first trimes-
ter of gestation [38].
All these issues make the quest for safe and effective alter-
natives to warfarin urgent. However, there is very little
information on warfarin alternatives in APS. Kaul et al ret-
rospectively followed up 54 APS patients on secondary
thrombosis prevention with aspirin, clopidogrel and low
molecular weight heparin. Over 2 years, recurrence rates
were 5.4, 9.1 and 3.1 per 100 patients years respectively
[40].
• Aspirin and antiplatelet agents
The APASS study identified aspirin as an adequate long
term treatment after non cardioembolic ischemic stroke
in a selected group of older patients with low positive aPL
[37]. Dersken et al reported a small cohort of 8 APS
patients in whom recurrent ischemic stroke rate was very
low on low dose aspirin [36]. In the APLASA study, a ran-
domized placebo controlled trial, asymptomatic persist-
ently aPL positive individuals (aCL IgG/IgM/IgA > 20 U
GPL and/or LA positive) did not benefit from low dose
aspirin (81 mg) for primary prevention of acute thrombo-
sis [41]. The overall acute thrombosis incidence rate in the
98 asymptomatic persistently positive aPL study subjects
was 1.33 per 100 patients-years; 2.75 per 100 patients-
years in the aspirin group and 0 per 100 patients years in
the placebo group (p = 0.83) [41].
Other antiplatelets agents, such as clopidogrel, ticlopidine
and aspirin/dipyridamole, that have been validated in
clinical trials for use in secondary prevention of ischemic
stroke and/or coronary artery disease in the general popu-
lation, have not been tested in APS.
• Heparins, Factor Xa inhibitors and thrombin inhibitors
Long term secondary prevention of venous thrombosis
with low molecular weight heparins is currently recom-
mended in oncological patients [16]. In these patients,
low molecular weight heparins were associated with sig-
nificantly fewer recurrent events when compared to warfa-
rin [42]. Data in non-oncological patients is scarce. Russel
et al randomized 737 patients to receive 3 months treat-
ment either with tinzaparin or standard warfarin for deep
vein thrombosis and showed similar effectiveness
between the two treatments [43]. Long term low molecu-
lar weight heparin therapy was associated with signifi-
cantly less overall bleeding (minor and major) events
when compared to standard care with warfarin (13% for
tinzaparin vs. 19.8% for warfarin; 95% CI; p = 0.011).
Mucosal bleeding was significantly less frequent in the
tinzaparin group (p = 0.003) [43].
In APS patients long term low molecular weight heparin
therapy has been empirically used when warfarin is no
longer possible, usually due to comorbidities that mark-
edly increase the risk of hemorrhage. In the absence of
prospective data and clinical trials, a few authors have
reported their empiric experience with this strategy as case
reports or small case series with conflicting results
[38,40,44].
Fondaparinux is a new subcutaneous anticoagulant that
indirectly inhibits Factor Xa. It has been shown to be safe
and effective in the acute treatment of deep vein thrombo-
sis and pulmonary emboli and also in venous thrombosis
prevention in patients undergoing hip and knee surgery
[45]. Indraparinux, a once weekly subcutaneous Factor Xa
inhibitor is still undergoing clinical trials. Neither have
been tested in APS patients.
Emerging oral anticoagulants, direct thrombin inhibitors
and direct Xa inhibitors, such as dabigatran, rivaroxaban
and apixaban, were developed as oral alternatives to war-
farin for extended treatment of venous thromboembolism
and are currently in clinical trials [46]. The role of dabigat-
ran and rivaroxaban in primary prevention of venous
thromboembolism after hip and knee arthroplasty has
recently been established [47-50]. Indeed, dabigatran is
already licenced for use and recommended by NICE as an
option for primary venous thrombosis prevention in
adults undergoing elective total hip or knee replacement
surgery [51].Journal of Autoimmune Diseases 2008, 5:6 http://www.jautoimdis.com/content/5/1/6
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• Other drugs
Recently, statins have been a new approach in drug ther-
apy in APS due to their antithrombotic, anti-inflamma-
tory and pleiotropic effects on vascular endothelium [52].
In fact, it has been shown that some statins can block the
aPL induced endothelial cell activation which is thought
to be a mechanism of thrombus formation in APS [53].
Hydroxychloroquine is widely used in lupus patients and
is thought to have a promising role in APS patients.
Hydroxychloroquine is known to have weak anticoagu-
lant properties and its use in SLE patients with APS has
been associated with a decreased risk of thrombosis [53].
Moreover, it has immunomodulatory effects that might
prove beneficial in APS [53].
Some authors have anedoctally reported the use of rituxi-
mab in selected APS patients when standard treatment
had failed, some with favorable outcome [54,55].
Unfortunately, much has yet to be done, since none of
these drugs have yet been studied in clinical trials with aPL
positive patients and effective alternative drugs still need
to be developed for the management of APS with throm-
bosis.
Unanswered questions
Evidence based medicine is often difficult to apply to indi-
vidual patients. This is especially true of randomised con-
trolled trials where patients are so highly selected that they
may not reflect routine clinical practice. The following sce-
narios illustrate the difficulties.
Scenario 1: a 30 year old lady diagnosed with APS 
following a left calf deep vein thrombosis after surgery 
with two positive LA tests more than twelve weeks apart
The duration of anticoagulant therapy after a venous
thromboembolic event has evolved towards a multifacto-
rial risk assessment and stratification based decision mak-
ing aimed at individually tailoring the optimal length of
treatment [56,57].
Among the diversity of factors considered in this process,
the presence, nature and reversibility of a triggering risk
factor is a major determinant of the duration of treatment
[56,57]. Patients developing deep vein thrombosis after
surgery (a major transient risk factor) are known to have a
very low estimated risk of recurrence compared to patients
with a permanent risk factor or an unprovoked event [58].
Fifty per cent of patients with APS have a triggering risk
factor at the time of a first thrombotic event [17]. How-
ever, no study has yet specifically addressed the influence
of triggering and additional risk factors on the risk of
recurrence in these patients. Thus their management relies
on expert opinion.
Additionally, some features of APS might prove useful in
risk stratification. For instance, LA is more strongly associ-
ated with thrombosis than aCL [10]. Whether this differ-
ence prevails when only recurrent thrombosis is
concerned is not known.
It is also unclear whether patients with APS associated
with SLE have a higher risk of recurrent events than
patients with APS without any underlying systemic dis-
ease. Patients with SLE and LA have a 50% chance of hav-
ing an arterial or venous event at 20 years of follow-up
[59]. However, as documented by Petri and Calvo-Alén et
al, SLE itself increases the risk of venous thromboembolic
events [60,61]. Twenty-one out of 760 SLE patients with
active disease (in the Hopkins Lupus Cohort) had a first
venous thromboembolic event during follow up, the inci-
dence rate of venous thrombosis being 1.0 per 100 per-
son-years (95% CI, 0.6 – 1.5) [60]. Fifty-one (9%) of 570
patients with SLE in the LUMINA cohort developed
venous thrombosis after the diagnosis of SLE [61]. Disease
activity was independently associated with venous throm-
bosis (HR 1.106, 95% CI 1.008 – 1.1213, p = 0.032) and
the venous thromboembolic events tended to occur early,
rather than late, after the diagnosis of SLE [61].
Following these observations, Merkel et al demonstrated
that patients with Wegener's granulomatosis are at
increased risk of venous thromboembolic events. The cal-
culated incidence rate was 7 per 100 person-years
(95%CI, 4.0 – 11.4), which is much higher than the inci-
dence in patients with systemic lupus erythematosus [1.0
(95% CI, 0.6–1.5)] and rheumatoid arthritis [0.26 (95%
CI, 0.1–0.5)] [60,62]. Additional risk factors for venous
thromboembolism, namely aPL, were not evaluated.
However, APS can occur in association with primary sys-
temic vasculitis. In a cross sectional study, aPL (aCL and/
or LA) were present in 25 (17%) out of 144 patients with
primary systemic vasculitis and 9 (6%) of 144 fulfilled cri-
teria for APS mainly due to arterial or venous thrombotic
events [63]. Nevertheless, just having Wegener's Granulo-
matosis itself seems to be a risk factor for venous throm-
bosis. In Merkel et al's study, the venous thromboembolic
events tended to occur during periods of active disease or
within 2 months of a disease flare [62].
In the past few years, a consistent and progressive increase
in the risk of recurrence has been associated with elevated
levels of d-dimers obtained one month after discontinua-
tion of anticoagulant therapy for a first venous throm-
boembolic event, and this risk was reduced by resumption
of anticoagulation [64]. In fact, d-dimer levels may prove
to be a useful tool in a risk stratification strategy and it
could be interesting to assess their role in the context of
APS [64].Journal of Autoimmune Diseases 2008, 5:6 http://www.jautoimdis.com/content/5/1/6
Page 8 of 12
(page number not for citation purposes)
Clinical practice point 1: This patient would be on indefinite
long term warfarin with a target INR 2.0 – 3.0. Moreover, and
if laboratory criteria are based on positive LA, once the patient
is on warfarin repeat testing is not possible, and though it can
be done in highly specialized centres the result can be difficult
to interpret.
Scenario 2: An 18 year old woman is diagnosed with APS 
following pulmonary emboli while on the oral 
contraceptive pill
Oral estrogen use in women is an established risk factor
for venous thromboembolism. Combined oral contracep-
tives are known to increase this risk by about two to six
fold in pre-menopausal women and hormone replace-
ment therapy by two to four fold [65]. Moreover, some
women who develop deep vein thrombosis while taking
combined oral contraceptives may have undetected APS
[66].
The diagnosis of APS with a venous thrombosis in the set-
ting of combined oral contraceptive use and positive aPL
raises two major issues: the optimal length of anticoagu-
lation therapy and alternative contraception methods.
In the absence of an evidence based risk stratified
approach to predict recurrent events, current empiric rec-
ommendations favour indefinite long term warfarin ther-
apy in these patients. As previously stated, available data
on recurrent venous thromboembolism in APS does not
address the optimal duration of anticoagulation and nor
does it include extensive evaluation of risk factors other
than aPL. In many cohorts, there are patients who for sev-
eral years do not have a recurrent event following discon-
tinuation of warfarin after a single thrombotic event
perhaps related to a well documented risk factor. These are
often patients in whom the diagnosis of APS was estab-
lished in retrospect as aPL were not tested at the time of
the event. Therefore, some experts have proposed that
some APS patients can empirically be considered to be at
low risk of recurrent thrombosis, in whom warfarin dis-
continuation could be considered: patients with a single
non-critical vascular thrombotic event developing in the
setting of a second transient risk factor (oral combined
contraceptive or hormone relacement therapy, pregnancy
or surgery) and who have been stable (without further
thrombotic events) for at least two years [38].
Clearly, venous thromboembolism and aPL positivity
absolutely contraindicates further oral estrogen use
[67,68]. Combined oral contraceptives have deleterious
hemostatic procoagulant effects, related to estrogen con-
tent, that favour venous thrombosis [67,69]. Oral pro-
gestins, such as chlromandinone acetate, levonorgestrel
and desogestrel, do not induce such hemostatic changes
and the few available data have shown progesterone only
contraceptives to be safe when used at contraception
doses [67,70,71]. A multicenter WHO international, case-
control collaborative study found no significant increase
in odds ratio for venous thromboembolism among pro-
gesterone only oral and injectable contraceptive users
[72]. Likewise, levonorgestrel only poscoital contracep-
tion, progesterone releasing IUD's and subdermal pro-
gestogen implants are not considered to increase the risk
of venous thromboembolism [67,68]. Conard et al have
shown that among 204 women with past venous throm-
bosis and/or hereditary thrombophilia, a progesterone
only oral contraceptive (chormandinone acetate) was not
associated with increased risk of venous thrombosis [71].
The Royal College of Obstetricians and Gynaecologists
advises against the use of oral combined contraceptives in
women with previous venous thromboembolism, and
considers the use of progesterone only contraception in
these women [73]. Indeed, the existing data comes from
studies in healthy indiciduals, in unselected patients with
venous thromboembolism and high risk patients with
thrombophilia (mainly hereditary) and venous thrombo-
sis. No study has specifically addressed APS patients who
need to be managed as being at high risk for venous
thrombosis.
Clinical practice point 2: This patient would be on indefinite
long term warfarin with a target INR 2.0 – 3.0. She would be
advised against the use of estrogen containing contraceptives.
Safe and effective alternatives such as progesterone only contra-
ceptives and barrier methods might be considered. Given that
she is aPL positive, a clinical assessment for other autoimmune
disorders including testing for antinuclear antibodies might
also be considered.
Scenario 3: A 40 year old patient with a pulmonary 
embolism and persistently low positive aPL
The clinical significance of low titre aCL is unclear. In a
prospective study where 412 patients were assigned to
warfarin treatment for 6 months after a first venous
thromboembolic and were tested at 6 months for aCL,
28% (17 out of 60) of patients with low positive titres (5
< Ig G aCL < 35 GPL U) and 37.5% (3 out of 8) of patients
with moderate to high titres (Ig G aCL > 35 GPL U) had
recurrent thromboembolic events at 4 years [25]. Never-
theless, in another study in which 360 patients with aPL
were prospectively followed up for 4 years no association
was found between low titre aCL and recurrent thrombo-
sis [22].
In fact, low titre aCL are not classification criteria for defi-
nite APS. Research studies, especially clinical trials, are
based on strict classification criteria that are highly spe-
cific and not sensitive in order to prevent bias and to ena-
ble the drawing of unequivocal conclusions. Therefore,Journal of Autoimmune Diseases 2008, 5:6 http://www.jautoimdis.com/content/5/1/6
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they rarely include patients with low titre aCL, and in
those studies that do include them the results have been
controversial. However, in clinical practice, in these
patients with low aCL titre, management decisions are not
clear cut but, nevertheless, do need to be considered.
Clinical practice point 3: Despite the low aCL, given the docu-
mented pulmonary embolism and persistence of the aPL, expert
opinion would support the use of indefinite long term warfarin
with a target INR 2.0 – 3.0 in addition to minimising other
risk factors.
Scenario 4: In a patient with APS and a single previous 
deep vein thrombosis, aPL become persistently negative on 
follow up
APS is considered an antibody mediated acquired pro-
thrombotic disorder, i.e., some aPL seem to be pivotal in
the pathogenesis of thrombosis, though the mechanisms
responsible for the emergence of the pathogenic antibod-
ies are not yet understood [2]. There are several types of
aPL but only some have been associated with the occur-
rence of clinical features and are therefore used in clinical
practice: IgG and IgM aCL, LA and anti β2 glycoprotein I
antibodies [1,2]. IgA aCL are not usually considered path-
ogenic. Antiphospholipid antibodies are known to fluctu-
ate with time. Discontinuing anticoagulation might be
argued in a patient with one venous thromboembolic
event whose aPL become persistently negative but there is
no prospective evidence to support this view. The absence
of the antibodies could indicate disease remission. On the
other hand, the aPL measured in clinical practice may sim-
ply reflect increased thrombosis risk and not necessarily
the actual pathogenic mechanism. At present, there is
absolutely no evidence to support management decisions.
Clinical practice point 4: In the setting of recurrent thromboem-
bolic events, this patient would be on indefinite long term war-
farin irrespective of the aPL status over time. In this patient
with a single venous thromboembolic event, discontinuing war-
farin therapy might be discussed individually with the patient,
with a careful explanation of a risk assessment and stratifica-
tion strategy for defining the optimal duration of anticoagulant
therapy. In the context of an associated autoimmune disease,
especially SLE or Wegener's granulomatosis, or other signifi-
cant cardiovascular risk factors, there would be a compelling
evidence based case for continuing indefinite long term warfa-
rin even if the aPL became negative.
Scenarios 5: A 60 year old woman with APS on warfarin 
following multiple pulmonary emboli has upper 
gastrointestinal bleeding from peptic ulceration
Bleeding is by far the most feared complication of any
anticoagulant therapy. Patients on warfarin have a 3%
yearly risk of major bleeding, which may occur even
within the therapeutic INR range (INR 2.0 – 3.0) [7,21].
Therefore, weighing the benefits of anticoagulation
against the risk of bleeding remain a constant concern
especially as patients age and acquire other bleeding risks
and co-morbid conditions.
On the whole, three situations may indicate anticoagula-
tion treatment to be reconsidered in patients on long term
warfarin: i) hemorrhagic complications; ii) recurrent
thromboembolic events despite optimal anticoagulant
management; iii) unmanageable INR not attributable to
lack of adherence to medication or diet or drug interac-
tions.
One rational clinical option might be to stop warfarin and
switch to long term low molecular weight heparin while
new, safe, effective and less cumbersome anticoagulant
drugs are being developed [20,21,74]. Low molecular
weight heparin treatment implies daily subcutaneous
injections but, unlike unfractioned heparin, does not
need regular monitoring or dose adjustments and is asso-
ciated with a significantly lower risk of heparin induced
thrombocytopenia and osteporosis [42]. Nonetheless,
regular platelet monitoring is needed and osteoporosis
risk assessment and prevention is recommended for good
clinical practice, when indefinite long term treatment is
being considered.
The studies on long term low molecular weight heparin
have addressed mainly oncological patients, in whom
they were shown to be more effective than vitamin K
antagonists for preventing recurrent venous thromboem-
bolism without increased bleeding [42]. Few data are
available concerning non-oncological patients with deep
vein thrombosis [42]. In patients with APS long term
treatment with low molecular weight heparin has been
increasingly suggested as an alternative to warfarin in
selected patients. Dentali et al anecdotally reported the
use of long term low molecular weight heparin in two
patients with APS and recurrent thrombosis despite opti-
mal anticoagulant therapy with successful outcomes [44].
However, no specific consistent data is available and its
use in these patients needs prospective evaluation.
Clinical practice point 5: This patient would stop warfarin until
the bleeding risk was controlled. The options would then
include either re-starting warfarin at a lower target INR of 2.5,
risking recurrent thrombosis but with a lower bleeding risk or
switching to indefinite long term low molecular weight heparin
adjusted to body weight. Platelet counts would be regularly
monitored (once a week in the first month and then once a
month). Osteoporosis prevention and regular screening would
be recommended.Journal of Autoimmune Diseases 2008, 5:6 http://www.jautoimdis.com/content/5/1/6
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Conclusion
In the antiphospholipid syndrome, the optimal duration
of warfarin therapy for secondary prevention of recurrent
venous thrombosis after a first venous thromboembolic
event remains controversial. Indefinite, life-long warfarin
therapy is currently the recommended standard of care.
The best available data to support this recommendation
have limitations and several questions remain unan-
swered. Discontinuing anticoagulation therapy in these
patients is presently not evidence based and may only be
considered in highly selected patients after careful coun-
selling and risk assessment. Likewise, it is unclear for how
long this therapy should be maintained. Indefinite long
term anticoagulation is considered beneficial for the
patient as long as the risk of bleeding does not outweigh
the benefits of treatment. Management decisions there-
fore merge between the available evidence and expert
opinion: evidence based versus eminence based medicine.
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